OR WAIT null SECS
Check out the latest features and columns!
Pharm Exec’s latest listing of the top global biopharma sales producers captures the critical business and public health balancing act that was required in the Year of COVID.
Read the profiles of 13 diverse leaders vital to the future of the biopharma industry.
July's Executive Profile features James Robinson, president and CEO of Urovant Sciences.
This Pharmaceutical CEO Leadership roundtable brings together pharma Chief Digital Officers and other leaders in the space to discuss the challenges and opportunities associated with digitizing all aspects of the pharma business.
The Healthcare Businesswomen’s Association again names Sandra Horning its WoTY—where the pharma leader’s message of purpose and partnership takes on added resonance today.
With a complicated and challenging global picture greeting the new year, driven by the continuing pandemic and historic political and regulatory changes in the US and Europe, we outline eight diverse trends critical to biopharma’s future health and growth.
Highlighted Videos
July 16, 2021
Transaction with special purpose acquisition company totals $138 million.
July 15, 2021
Closing the gap between promise and progress.
Grünenthal‘s Florent Edouard talks about AI‘s “key role in the future of marketing.”
July 14, 2021
A focus on medical affairs and medical science liaisons.
New cell and gene therapy commercialization network set to support small and midsize biotechs.
A broad White House proposal to advance competition in major U.S. industries features several measures intended to make medicines more affordable for patients.
July 13, 2021
Understanding of recent legal developments can help companies avoid infringement.
GSK‘s President of US Pharmaceuticals, Maya Martinez-Davis, outlines her organization’s evolving diversity and inclusion commitments.
The benefits of diversity in the workplace are far-reaching — not just for employees, but for a company’s overall health.
Marcelo Bigal, M.D, Ph.D, President and CEO of Ventus Therapeutics, talks about how technological innovation in the field of small molecule drug development has created new opportunities for pursuing undruggable targets, building on the well-established strengths of small molecule medicines.
